Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial

Domenica Lorusso, Giovanni Scambia, Maria Gabriella Ferrandina, Vanda Salutari, Stefano Greggi, Gennaro Daniele, Sabrina C. Cecere, Maria Ornella Nicoletto, Enrico Breda, Nicoletta Colombo, Grazia Artioli, Lucia Cannella, Giovanni Lo Re, Francesco Raspagliesi, Giuseppa Maltese, Alessandra Baldoni, Alice Bergamini, Maria Carmela Piccirillo, Germana Tognon, Irene FlorianiSimona Signoriello, Francesco Perrone, Sandro Pignata

Risultato della ricerca: Contributo in rivistaArticolo in rivista

21 Citazioni (Scopus)

Abstract

Background Few data are available on the outcome of surgery after a bevacizumab-containing regimen. The MITO 16A- MaNGO OV2A phase 4 trial evaluates the outcomes of first-line CPB in a clinical-practice-like setting. Here we present the results of the subgroup of patients undergoing IDS after neoadjuvant treatment or suboptimal primary surgery. Methods 400 chemonaïve epithelial ovarian cancer patients, age ≥ 18, ECOG PS 0–2 were eligible to receive C (AUC 5 d1, q21) plus P (175 mg/m2d1, q21) and B (15 mg/kg d1 q21) for 6 cycles followed by B maintenance until cycle 22nd. Results 79 patients (20%) underwent IDS. Overall, 74 patients received at least one administration of B before IDS. Median age was 61.2, 70% of the patients had FIGO IIIC disease. The median number of cycles before IDS was 3 both for chemotherapy and bevacizumab respectively. A residual disease ≤ 1 cm was achieved in 64 patients (86.5%). Four percent of the patients experienced fever and 4% required blood transfusion after surgery. Surgical wound infection and/or dehiscence, pelvic abscess, intestinal sub-occlusion and fistula were experienced by one patient each. Conclusions In the MITO16A-MaNGO OV2A phase 4 trial, combined chemotherapy and bevacizumab did not hamper IDS and the rate of perioperative complications was similar to what expected without bevacizumab. These data support the hypothesis that adding bevacizumab to first line chemotherapy for ovarian cancer might not be denied to patients for whom IDS is planned.
Lingua originaleEnglish
pagine (da-a)256-259
Numero di pagine4
RivistaGynecologic Oncology
Volume144
DOI
Stato di pubblicazionePubblicato - 2017

Keywords

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Bevacizumab
  • Carboplatin
  • Combined Modality Therapy
  • Cytoreduction Surgical Procedures
  • Feasibility Studies
  • Female
  • Humans
  • Interval debulking
  • Middle Aged
  • Neoadjuvant
  • Neoplasms, Glandular and Epithelial
  • Obstetrics and Gynecology
  • Oncology
  • Ovarian Neoplasms
  • Ovarian cancer
  • Paclitaxel
  • Surgery

Fingerprint Entra nei temi di ricerca di 'Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial'. Insieme formano una fingerprint unica.

Cita questo